Psychopharmacology
February 1, 2018
Liana Fattore, Alessandro Piva, Mary Tresa Zanda et al.
Clinical data with 3,4-methylenedioxymethamphetamine (MDMA) in post-traumatic stress disorder (PTSD) patients recently stimulated interest on the potential therapeutic use of psychedelics in disorders characterized by maladaptive memories, including substance use disorders (SUD). The rationale for the use of MDMA in PTSD and SUD is being extended to a broader beneficial "psychedelic effect,"...
British Journal of Pharmacology
October 1, 2017
Mary T. Zanda, Paola Fadda, S Antinori et al.
Methoxetamine (MXE) is a novel psychoactive substance that is emerging on the Internet and induces dissociative effects and acute toxicity. Its pharmacological effects have not yet been adequately investigated. We examined a range of behavioural effects induced by acute administration of MXE (0.5-5 mg·kg-1 ; i.p.) in rats and whether it causes rapid neuroadaptive molecular changes. MXE (0.5-5...
Behavioural Pharmacology
September 1, 2016
Mary T. Zanda, Paola Fadda, Cristiano Chiamulera et al.
An increasing number of novel psychoactive substances are currently available and sold as ‘legal highs’ or ‘research chemicals’ accompanied by the indication that they are ‘not for human consumption’. Among those that have emerged in the last few years, methoxetamine (MXE) owes its wide popularity to its easy access on the Internet and its reputation of being a ‘safe’ drug. MXE is an...
Psychopharmacology
June 1, 2016
Anna Mutti, Sonia Aroni, Paola Fadda et al.
Recently, an increasing number of emergency cases due to a novel ketamine-like drug, methoxetamine (MXE), were reported in several countries. However, very little is known about the neuropsychopharmacological and reinforcing profile of this compound. Our study aims to investigate the effects of MXE on self-administration (SA) behaviour in comparison to ketamine and on dopaminergic transmission....
Behavioural Pharmacology
April 1, 2016
Cristiano Chiamulera, Federica Armani, Anna Mutti et al.
Methoxetamine (MXE) is a chemical analogue of ketamine. Originally proposed as a ketamine-like fast-acting antidepressant, owing to similar N-methyl-D-aspartate blocker properties, it is now scheduled for reports of hallucinations and psychosis similar to ketamine and lysergic acid. As little is known about the addictive properties of MXE, the aim of this study was to investigate the similarity...